After Natera announced it would be presenting new data from the GALAXY observational arm of the CIRCULATE-Japan trial at the 2024 European Society for Medical Oncology, or ESMO, Congress from September 13-16 and provided takeaways from this data, including a 10-times advantage to colorectal cancer patient’s overall survival that tested Signatera-negative, Canaccord analyst Kyle Mikson noted that the results compare favorably to guideline recommended biomarkers. The firm, which notes that Natera expects to provide a top-line data readout for the ALTAIR study in roughly January 2025, contends that results from these studies could lead to inclusion in National Comprehensive Cancer Network, or NCCN, guidelines and expanded commercial coverage for Signatera. The firm reiterates its Buy rating on Natera shares with a price target of $145.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Election 2024: Where To Put Your Money Ahead of the Vote
- Natera price target raised to $145 from $130 at Canaccord
- Natera price target raised to $132 from $125 at Morgan Stanley
- Natera price target raised to $150 from $120 at Piper Sandler
- Cathie Wood’s ARK Investment bought 43.6K shares of Natera today